Jazz Pharmaceuticals and Gentium S.p.A. Announce Agreement for Jazz Pharmaceuticals to Acquire Gentium for $57.00 Per Share Transaction would add a significant growth product in the European Union and Rest of World markets, Defitelio , a treatment for severe hepatic veno-occlusive disease in adults and children undergoing hematopoietic stem cell ... (more)
http://www.globenewswire.com/news-release/2013/12/19/598376/10062111/en/Jazz-Pharmaceuticals-and-Gentium-S-p-A-Announce-Agreement-for-Jazz-Pharmaceuticals-to-Acquire-Gentium-for-57-00-Per-Share.html
http://www.globenewswire.com/news-release/2013/12/19/598376/10062111/en/Jazz-Pharmaceuticals-and-Gentium-S-p-A-Announce-Agreement-for-Jazz-Pharmaceuticals-to-Acquire-Gentium-for-57-00-Per-Share.html
No comments:
Post a Comment